Toronto Dominion Bank Has $36.37 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Toronto Dominion Bank grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 7.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 160,305 shares of the medical instruments supplier's stock after acquiring an additional 10,719 shares during the period. Toronto Dominion Bank owned 0.06% of Becton, Dickinson and Company worth $36,367,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Brighton Jones LLC grew its holdings in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after acquiring an additional 877 shares in the last quarter. E. Ohman J or Asset Management AB grew its holdings in shares of Becton, Dickinson and Company by 13.4% during the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier's stock valued at $39,951,000 after acquiring an additional 20,859 shares in the last quarter. Busey Bank grew its holdings in shares of Becton, Dickinson and Company by 3.8% during the 4th quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier's stock valued at $15,031,000 after acquiring an additional 2,399 shares in the last quarter. Swedbank AB grew its holdings in shares of Becton, Dickinson and Company by 1.0% during the 4th quarter. Swedbank AB now owns 152,293 shares of the medical instruments supplier's stock valued at $34,551,000 after acquiring an additional 1,455 shares in the last quarter. Finally, Phraction Management LLC grew its holdings in shares of Becton, Dickinson and Company by 7.2% during the 4th quarter. Phraction Management LLC now owns 47,021 shares of the medical instruments supplier's stock valued at $10,668,000 after acquiring an additional 3,138 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Michael David Garrison sold 479 shares of the company's stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the transaction, the executive vice president now owns 4,887 shares of the company's stock, valued at approximately $964,107.36. This represents a 8.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Richard Byrd sold 459 shares of the company's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total transaction of $105,570.00. Following the transaction, the executive vice president now directly owns 6,952 shares of the company's stock, valued at $1,598,960. This represents a 6.19% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,878 shares of company stock valued at $636,393. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Performance

BDX stock traded down $1.29 during mid-day trading on Friday, reaching $172.53. 3,358,673 shares of the stock traded hands, compared to its average volume of 1,928,632. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The business has a 50-day moving average of $192.64 and a two-hundred day moving average of $216.63. The firm has a market capitalization of $49.45 billion, a PE ratio of 28.66, a P/E/G ratio of 1.63 and a beta of 0.31.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The company had revenue of $5.27 billion during the quarter, compared to analysts' expectations of $5.35 billion. During the same period in the prior year, the company earned $3.17 earnings per share. The business's quarterly revenue was up 4.5% compared to the same quarter last year. As a group, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.41%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 79.39%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Wells Fargo & Company cut shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a report on Thursday, May 1st. Piper Sandler cut shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $260.00 to $185.00 in a report on Friday, May 2nd. Barclays decreased their price objective on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating for the company in a report on Monday, April 7th. Stifel Nicolaus decreased their price objective on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Finally, Citigroup cut shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and decreased their price objective for the stock from $217.00 to $185.00 in a report on Thursday, May 22nd. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $221.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.